Bioequivalence Study,
Conditions
Interventions
coated tablet,
CRESTOR 20 mg,
manufactured by IPR Pharmaceuticals Inc.,
Puerto Rico and imported by AstraZeneca (Thailand) Ltd.,
Bangkok,
Thailand. Each tablet contains 20 mg of rosuvastatin as rosuvastatin calcium.,Generic rosuvastatin 20 mg film-
Active Comparator Drug,Active Comparator Drug
Rosuvastatin plasma concentration (reference product),Rosuvastatin plasma concentration (test product)
Sponsors
International Bio Service Co. Ltd
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1.Healthy Thai male or female subjects between the ages of 18 to 55 years. 2.Body mass index between 18.0 to 30.0 kg/m2. 3.Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study. 4.Non-pregnant woman (negative pregnancy test) and not currently breast feeding. 5.Female subjects abstain from either hormonal methods of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to admission in Period 1. Injectable contraceptives e.g. Depo-Provera® will be discontinued at least 6 months prior to admission in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to admission in Period 1 until 7 days after the end of study in Period 2. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to admission in Period 1:  Postmenopausal for at least 1 year or  Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months. 6.Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after check-in in Period 1 until 7 days after the end of study in Period 2. 7. Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study.
Exclusion criteria
Exclusion criteria: 1.History of allergic reaction or hypersensitivity to rosuvastatin or to any of the excipients of the product. 2.History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological (e.g. anemia), endocrine (e.g. hyper-/hypothyroid), pulmonary or respiratory (e.g. asthma), cardiovascular (e.g. hyper-/hypotension), psychiatric, neurologic (e.g. convulsant), allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness 3. History of muscular diseases i.e. myopathy, myalgia, rhabdomyolysis, muscle tenderness or weakness or hereditary muscular disorders or history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate 4.History or evidence of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption 5. History of problems with swallowing tablet or capsule 6. History of sensitivity to heparin or heparin-induced thrombocytopenia 7. Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy 8.History of preceding diarrhea within 24 hours prior to check-in in each period 9.History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine) 10.12-lead ECG demonstrating QTc >450 msec, a QRS interval >120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG will be repeated two more times and the average of the three QTc or QRS values will be used to determine the subject’s eligibility. 11.Investigation with blood sample shows positive test for HBsAg. 12.Abnormal liver function, ≥ 1.5 times of upper normal limit of reference range for ALT, AST or bilirubin levels at screening laboratory test 13.Creatine kinase levels 1.5 times of upper normal limit of reference range (unless explained by exercise) at screening laboratory test 14.Have renal creatinine clearance (Clcr) <30 mL/min based on serum creatinine results, using glomerular filtration rate (GFR; Cockcroft-Gault formula), at the screening laboratory test 15.History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 48 hours prior to check-in and continued for entire duration of the study 16.History or evidence of alcoholism or harmful use of alcohol (less than 2 years) i.e., alcohol consumption of more than 14 standard drinks per week for men and 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40% distilled spirits, such as rum, whisky, brandy etc.) 17.History or evidence of alcohol consumption or alcohol-containing products and cannot abstain for at least 48 hours prior to check-in and continued for entire duration of the study or alcohol breath test shows positive result In case of alcohol breath test result represents the alcohol concentration range of 1 - 10 mg% BAC and the physician carefully considers that the value came from other reasons, not from the alcohol drinking behavior of subjects, the test will be repeated two times separately, not more t
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rosuvastatin plasma concentration 0-72 hr Cmax, AUC0-tlast and AUC0-∞ will be determined from the plasma concentration data of analytes. | — |
Secondary
| Measure | Time frame |
|---|---|
| Rosuvastatin plasma concentration 0-72 hr Tmax, t1/2, AUC0-tlast/AUC0-∞, AUC%extrapolate, λz and MRT will be determined from the plasma con | — |
Countries
Thailand
Contacts
Public ContactPorranee Puranajoti
International Bio Service Co. Ltd
Outcome results
None listed